Gerresheimer’s 90% Volatility Tells a Tale of Two Crises

Gerresheimer faces a multi-layered crisis: factory closure, BaFin probe, KPMG scrutiny, and a September 2026 creditor deadline, despite a 22% stock rally.

The stock is up 22% in a month, yet Gerresheimer is closing a factory, fending off regulators, and racing a September 2026 creditor deadline. The disconnect between market optics and operational reality has rarely been starker.

On Tuesday, the packaging group announced it will shutter its Chicago Heights facility by the end of September 2026, eliminating 172 jobs. Production will shift to existing plants in Italy and India. A spokesman cited the need to boost efficiency across the global network. The restructuring carries a heavy non-cash charge: impairment losses of between €220 million and €240 million for fiscal 2025, hitting primarily the US site and the Sensile Medical AG subsidiary.

The factory closure is just one front in a multi-layered crisis. The accounting scandal that erupted late last year continues to widen. Germany’s financial watchdog BaFin launched a probe into the consolidated interim accounts on March 6, 2026, focusing on three specific allegations: leasing liabilities of €65.5 million reported at incorrect levels; capitalised development costs with a book value of €29.4 million carrying misstated useful lives; and assets in the Advanced Technologies segment with a book value of roughly €196 million that were not properly impaired.

The root cause traces back to so-called bill-and-hold arrangements — Gerresheimer invoiced customers for goods but delayed delivery, booking revenue prematurely in violation of IFRS rules. An independent law firm confirmed the systematic breaches, which hit revenue by €35 million and adjusted EBITDA by €24 million.

Now the pressure is mounting on the auditor. The Abschlussprüferaufsichtsstelle (APAS), Germany’s audit oversight body, has opened a professional conduct case against KPMG, which took over from Deloitte in 2024 and promptly issued an unqualified opinion on the 2024 annual accounts despite what regulators say were systemic IFRS errors.

Without a signed-off annual report, the stock remains effectively uninvestable for many institutional investors. STOXX’s decision to eject Gerresheimer from the SDAX index after the missed filing deadline has compounded the problem. The annualised 30-day volatility now sits at roughly 90%, making it one of the most jittery names in the German healthcare sector.

The shares changed hands at €24.18 on Tuesday, roughly 60% below their 52-week high. While that marks a recovery from the February trough, the stock still trades well below its 200-day moving average. Barclays downgraded the equity to “Underweight” on the same day, citing the lingering uncertainty from delayed financial reports and ongoing regulatory probes.

Management is trying to buy time on two fronts. The company has secured a creditor extension that runs until September 2026 — the same month the Chicago plant is due to close. To shore up the balance sheet, Gerresheimer is pressing ahead with the sale of its US subsidiary Centor, which makes packaging systems for prescription drugs. Morgan Stanley is handling the process, and a double-digit number of interested parties have emerged. A deal is expected to close sometime in 6.

The make-or-break date remains June 2026. That is when Gerresheimer plans to publish its audited annual and consolidated accounts for fiscal 2025, along with its first-quarter 2026 trading update. The half-year report is scheduled for July 14, 2026. Until then, the company is sticking to its full-year guidance: revenue of €2.3 billion to €2.4 billion and an adjusted EBITDA margin of 18% to 19%. Day-to-day operations are said to be running in line with expectations, and the order book is described as solid.

But the arithmetic is unforgiving. If the June deadline slips, the September creditor reprieve could evaporate, leaving Gerresheimer with a closed factory, a regulatory cloud, and a stock that no institution can touch.